查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
齐拉西酮全球市场-2022-2029
市场调查报告书
商品编码
1129251

齐拉西酮全球市场-2022-2029

Global Ziprasidone Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

预计全球精神疾病的流行将推动市场增长。

根据世界卫生组织 (WHO) 的说法，精神分裂症会导致精神病，与相当大的残疾有关，并且会影响生活的所有领域，包括个人、家庭、社会、教育和职业功能。它一直存在。据说精神分裂症影响全球约 2400 万人，即 300 人中有 1 人（0.32%）。在成人中，这一比例为 222 分之 1（0.45%）。它不像许多其他精神疾病那样普遍。因此，某些精神疾病的增加增加了对该药的需求，该药主要以齐拉西酮治疗。

此外，推荐使用这种药物，因为它具有明显的即时效果和立即缓解症状。此外，Reddy 博士于 2020 年 3 月 17 日宣布推出甲磺酸齐拉西酮，旨在通过增加药房的价值使医疗保健更实惠。因此，从上述陈述来看，预计将在预测期内推动市场。

与齐拉西酮相关的副作用预计会阻碍市场增长。

齐拉西酮是一种会增加体重增加、糖尿病和高胆固醇风险的药物。此外，如果患者有心律失常、长 QT 综合征或不受控制的心力衰竭病史，则不鼓励使用齐拉西酮，从而减少对该产品的需求。齐拉西酮的低需求是由于呼吸道感染、锥体外系症状、静坐不能、视力模糊、头晕、呕吐、头痛和噁心等副作用。同样，氟□啶醇、奎硫平和阿立□唑等更有效替代品的出现将减少齐拉西酮的市场需求。此外，使用该产品引起的代谢综合征的健康危害预计将阻碍预测期内的市场增长。

行业分析

齐拉西酮市场根据各种行业因素（包括供应链分析、定价分析等）对市场进行深入分析。

COVID-19 影响分析

COVID-19 大流行对医疗保健系统和市场产生了适度影响。 COVID-19 影响人们的心理健康和生活质量。 COVID-19 会引起恐慌、焦虑、抑郁和失眠，尤其是在患者和医护人员中。可能会为 COVID-19 患者开具精神科药物。此外，一些 COVID-19 患者出于各种原因使用精神科药物。因此，精神科药物和用于治疗 COVID-19 的药物之间存在药物相互作用 (DDI) 的风险。细胞色素 P450 系统负责几种精神药物的代谢。

另一方面，大流行会破坏供应炼和流程。许多公司将转移到其他地区以确保产品可用性并保护其供应链。因此，从上面这句话来看，市场受到了影响，预计随着经济活动的恢復，市场将迅速获得牵引力。

全球齐拉西酮市场报告将提供对大约 45 多个市场数据表、40 多个数字和 180 页的访问。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因子
    • 驱动程序
      • 预计全球精神疾病的流行将推动市场增长。
    • 限制因素
      • 与齐拉西酮相关的副作用预计会阻碍市场增长。
    • 市场机会
    • 影响分析

第五章行业分析

  • 供应链分析
  • 定价分析
  • 未满足的需求分析
  • 管道分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章给药途径

  • 口服胶囊
  • 肌肉注射
  • 其他

第 8 章按应用程序

  • 精神分裂症
  • 躁郁症
  • 激动
  • 其他

第 9 章按销售渠道

  • 医院药房
  • 在线药店
  • 零售店
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表

第 12 章公司简介

  • Pfizer Inc
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Sandoz AG
  • Lupin Pharmaceuticals, Inc.
  • Mylan Pharmaceuticals
  • Apotex
  • Dr. Reddy's laboratories Ltd.
  • Wockhardt
  • Aurobindo Pharma USA

第 13 章齐拉西酮-DataM 全球市场

简介目录
Product Code: DMPH5804

Market Overview

The Ziprasidone Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Ziprasidone, commonly known as Geodon, is an atypical antipsychotic of the second generation that is used to treat schizophrenia and bipolar disorder, among other things. The pills include hydrochloride salt and ziprasidone hydrochloride, which rebalances dopamine and serotonin in the brain to improve mood and behavior.

Market Dynamics

The increasing prevalence of mental disorders worldwide is expected to drive market growth.

According to the World Health Organization, Schizophrenia causes psychosis, is associated with considerable disability and may affect all areas of life, including personal, family, social, educational, and occupational functioning. Schizophrenia affects around 24 million people globally or one in every 300 people (0.32 percent). Adults have a rate of 1 in 222 (0.45 percent). It is not as widespread as many other mental illnesses. Therefore, the demand for the medication has increased due to an increase in certain mental health conditions, which are largely treated with Ziprasidone.

Furthermore, the medicine is recommended because of the immediate effect visible when delivering the dose, resulting in immediate alleviation. Moreover, Dr. Reddy's announced the launch of Ziprasidone Mesylate on March 17, 2020, intending to make healthcare more affordable by giving value to the pharmacy. Thus, from the above statements, the market is expected to drive in the forecast period.

Side effects associated with ziprasidone are expected to hamper the market growth.

Ziprasidone is a medicine that increases the risk of weight gain, diabetes, and high cholesterol. Also, using ziprasidone is not recommended if the patient has a history of heart rhythm disorders, long QT syndrome, or uncontrolled heart failure, which diminishes the product's demand. Ziprasidone's low demand is due to side effects such as respiratory tract infections, extrapyramidal symptoms, akathisia, altered eyesight, dizziness, vomiting, headache, and nausea. Likewise, the availability of more effective alternatives like haloperidol, quetiapine, and aripiprazole diminishes market demand for ziprasidone. The metabolic syndrome health hazards associated with utilizing the product will hamper the market growth in the forecast period.

Industry Analysis

The ziprasidone market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. COVID-19 has an impact on people's mental health and quality of life. COVID-19 induces panic, anxiety, depression, and insomnia, particularly in patients and health care workers. Patients with COVID-19 may be prescribed mental medications. In addition, some COVID-19 patients have been using psychiatric medicines for various reasons. As a result, there is a risk of drug-drug interaction (DDI) between psychiatric medicines and drugs used to treat COVID-19. The cytochrome P450 system is responsible for the metabolism of several psychiatric medications.

In contrast, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Oral Capsules segment is expected to hold the largest market share in ziprasidone market

The oral capsules segment is expected to dominate in 2021. The segment benefits because the capsules have been approved by the US Food and Drug Administration (FDA) for long-term treatment of individuals with bipolar disorder due to their effectiveness and patient tolerability. The simplicity of long-term usage required due to the chronic nature of the sickness and the requirement of lesser doses of the medicine to be given at different times to improve the efficacy of the treatment also contribute to the demand. Oral capsules are less likely to cause an overdose. Oral capsules for Ziprasidone are less expensive than injections, making the medication more accessible and increasing demand. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global ziprasidone market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of bipolar disorders, high adoption of ziprasidone drugs, product launches and acquisitions by the market key players and rising clinical trials in the region are some factors the market is expected to boost in the forecast period. For instance, according to the National Institute of Mental Health, Bipolar disorder affects approximately 5.7 million adult Americans, or about 2.6% of the U.S. age 18 and older every year. Moreover, bipolar illness affects an equal number of men and women and affects people of all ages, races, ethnic groups, and social classes. Additionally, Upjohn, a part of Pfizer, announced the completion of the Phase 3 pediatric clinical trial for Geodon on November 10, 2020. (ziprasidone). The study looked at the efficacy and safety of ziprasidone in children and adolescents with bipolar I disorder. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the ziprasidone market are Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals, Inc., Mylan Pharmaceuticals, Apotex, Dr. Reddy's laboratories Ltd. , Wockhardt, Aurobindo Pharma USA.

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

Product Portfolio:

GEODON (ziprasidone HCl): GEODON Capsules are indicated for treating schizophrenia in adults, acute treatment in adults as monotherapy of manic or mixed episodes associated with bipolar I disorder, and maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults.

The global ziprasidone market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing prevalence of mental disorders worldwide is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with ziprasidone are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs
  • 5.4. Pipeline Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Route of Administration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 7.2. Oral Capsules*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Intramuscular Injection
  • 7.4. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Schizophrenia*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Bipolar Mania
  • 8.4. Agitation
  • 8.5. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Pfizer Inc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sandoz AG
  • 12.3. Lupin Pharmaceuticals, Inc.
  • 12.4. Mylan Pharmaceuticals
  • 12.5. Apotex
  • 12.6. Dr. Reddy's laboratories Ltd.
  • 12.7. Wockhardt
  • 12.8. Aurobindo Pharma USA

LIST NOT EXHAUSTIVE

13. Global Ziprasidone Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us